Park Place Capital Corp Sells 52 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Park Place Capital Corp lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 478 shares of the medical research company’s stock after selling 52 shares during the quarter. Park Place Capital Corp’s holdings in Charles River Laboratories International were worth $99,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. DAVENPORT & Co LLC acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $1,904,000. Arizona State Retirement System raised its position in Charles River Laboratories International by 0.9% in the 4th quarter. Arizona State Retirement System now owns 14,091 shares of the medical research company’s stock valued at $3,331,000 after purchasing an additional 127 shares during the last quarter. Fulton Bank N.A. raised its position in Charles River Laboratories International by 6.6% in the 4th quarter. Fulton Bank N.A. now owns 3,108 shares of the medical research company’s stock valued at $735,000 after purchasing an additional 193 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in Charles River Laboratories International by 98.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after purchasing an additional 6,997 shares during the last quarter. Finally, Equitable Trust Co. raised its position in Charles River Laboratories International by 33.8% in the 4th quarter. Equitable Trust Co. now owns 2,282 shares of the medical research company’s stock valued at $539,000 after purchasing an additional 576 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 3.8 %

NYSE:CRL traded down $9.24 on Friday, reaching $233.60. The company’s stock had a trading volume of 567,961 shares, compared to its average volume of 558,970. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The firm has a market cap of $12.03 billion, a PE ratio of 27.48, a PEG ratio of 2.32 and a beta of 1.38. The business’s 50-day moving average price is $215.07 and its two-hundred day moving average price is $231.43.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the subject of a number of recent research reports. TD Cowen dropped their target price on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. The Goldman Sachs Group initiated coverage on Charles River Laboratories International in a research report on Thursday, June 6th. They set a “buy” rating and a $290.00 target price for the company. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Finally, Mizuho initiated coverage on Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $252.29.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).